Aarey Drugs & Pharmaceuticals Ltd.
•Add ratio to table
ABOUT
AI Sector View
AI GENERATEDOil Gas & Consumable Fuels
Sector economics are clouded by input volatility and uneven volume trends. WPI fuel inflation is very high at 20.05% (Jul/26), crude oil output is -5.3% YoY (2026-07), natural gas is -3.7% YoY (2026-07), and natural gas consumption is -3.0% YoY (2026-06), although refinery products grew 2.7% YoY (2026-07) and coal was 7.6% YoY (2026-07). Heavy FPI outflows of INR -15293 crore over 3 months to 2026-08-31 and negative oil-linked news flow reinforce the underweight.
PROS
- Institutional investors have been accumulating - FII+DII up 2.8pp
- Company maintains a comfortable, low leverage position
- Company converts assets efficiently - asset turnover of 1.6x
CONS
- A large part of profit comes from other income (160.8% of PBT)
- Company has a low return on equity of 3.4% over last 3 years
- Company has a low return on capital employed of 6.2%
- Promoter holding has decreased over last 2 years: -7.6pp
- Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.48x)
- Operating cash flow has been negative in recent years
* The pros and cons are machine generated based on quantitative rules.
Peer comparison
| Name | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| ADANIENT | 2886.00 | 52.48 | 390684.34 | 0.04 | -1461.54 | -249.67 | 32923.98 | 49.92 | 13.30 | 15.57 |
| PREMIERENE | 1002.00 | 27.32 | 45485.94 | 0.10 | 471.92 | 53.32 | 2462.59 | 35.25 | 33.72 | 29.03 |
| AEGISLOG | 1286.15 | 36.08 | 45143.87 | 0.68 | 544.84 | 210.70 | 2356.86 | 37.07 | 19.76 | 30.28 |
| CPPLUS | 3748.55 | 92.91 | 44345.51 | 0.04 | 142.20 | 332.51 | 1402.42 | 89.51 | 29.48 | 14.52 |
| REDINGTON | 372.40 | 17.12 | 29113.28 | 1.61 | 453.49 | 94.65 | 34922.47 | 34.57 | 18.96 | 2.03 |
| HONASA | 477.45 | 62.55 | 15566.03 | 0.63 | 90.45 | 118.87 | 755.95 | 27.00 | 8.99 | 14.58 |
| LLOYDSENT | 71.95 | 97.81 | 10983.54 | 0.21 | 109.98 | -55.77 | 563.03 | 70.15 | 12.84 | 18.07 |
| SGMART | 814.50 | 82.57 | 10265.57 | 0.00 | 455.80 | 1310.71 | 13085.70 | 1044.08 | 10.43 | 4.49 |
| MMTC | 62.28 | 20.88 | 9342.00 | 0.00 | 104.24 | 135.52 | 0.68 | -50.00 | 33.46 | -1423.53 |
| ENTERO | 1847.60 | 64.12 | 8041.32 | 0.00 | 52.05 | 72.17 | 1940.50 | 38.23 | 10.93 | 5.00 |
| CELLO | 343.50 | 24.77 | 7747.24 | 0.44 | 73.40 | -8.99 | 526.72 | -0.43 | 17.15 | 18.80 |
| AAREYDRUGS | 94.84 | 70.12 | 292.81 | 0.00 | 1.02 | -25.26 | 44.63 | -56.34 | 6.38 | 2.97 |
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 51 | 58 | 76 | 210 | 127 | 105 | 134 | 108 | 102 | 84 | 96 | 189 | 45 | |
| 50 | 56 | 74 | 212 | 126 | 101 | 132 | 112 | 101 | 82 | 98 | 185 | 46 | |
| Operating Profit | 1 | 2 | 3 | -1 | 1 | 4 | 2 | -4 | 2 | 3 | -2 | 4 | -1 |
| OPM % | 2.63% | 3.20% | 3.54% | -0.68% | 0.93% | 3.54% | 1.64% | -3.89% | 1.66% | 3.14% | -1.57% | 2.29% | -2.69% |
| 1 | 1 | 0 | 5 | 2 | 0 | 1 | 8 | 2 | 1 | 4 | -0 | 2 | |
| Interest | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 |
| Profit before Tax | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 |
| Tax % | 0.00% | 21.78% | 30.14% | -0.47% | 6.77% | 8.57% | 48.57% | 71.60% | 20.81% | 31.08% | 38.04% | -21.88% | -98.64% |
| Net Profit | 1 | 1 | 1 | 2 | 1 | 2 | 1 | 0 | 1 | 1 | 1 | 2 | 1 |
| 0.29 | 0.31 | 0.40 | 0.77 | 0.44 | 0.57 | 0.26 | 0.17 | 0.48 | 0.36 | 0.20 | 0.55 | 0.36 |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 246 | 396 | 349 | 355 | 300 | 348 | 493 | 419 | 398 | 474 | 415 | |
| 245 | 386 | 341 | 347 | 297 | 344 | 481 | 411 | 391 | 471 | 410 | |
| Operating Profit | 1 | 10 | 8 | 8 | 3 | 5 | 11 | 8 | 6 | 3 | 4 |
| OPM % | 0.41% | 2.43% | 2.19% | 2.22% | 1.08% | 1.33% | 2.31% | 1.84% | 1.63% | 0.61% | 1.03% |
| 3 | 3 | 3 | 4 | 7 | 7 | 3 | 3 | 5 | 10 | 6 | |
| Interest | 2 | 4 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 |
| Profit before Tax | 2 | 8 | 8 | 9 | 7 | 8 | 10 | 6 | 5 | 6 | 4 |
| Tax % | 28.88% | 31.39% | 24.59% | 27.20% | 20.00% | 21.53% | 34.69% | 37.25% | 12.34% | 34.05% | 0.52% |
| Net Profit | 1 | 5 | 6 | 7 | 6 | 7 | 7 | 4 | 5 | 4 | 4 |
| EPS | 0.77 | 3.03 | 2.64 | 2.64 | 2.80 | 2.79 | 2.72 | 1.49 | 1.67 | 1.41 | — |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 3.57% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — |
COMPOUNDED SALES GROWTH
- 10 Years:
- 8%
- 5 Years:
- 10%
- 3 Years:
- -1%
COMPOUNDED PROFIT GROWTH
- 10 Years:
- 14%
- 5 Years:
- -7%
- 3 Years:
- -15%
STOCK PRICE CAGR
- 10 Years:
- —
- 5 Years:
- 21%
- 3 Years:
- 22%
- 1 Year:
- 39%
RETURN ON EQUITY
- 10 Years:
- 6%
- 5 Years:
- 5%
- 3 Years:
- 3%
- Last Year:
- 3%
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 17 | 18 | 23 | 23 | 23 | 23 | 25 | 25 | 28 | 28 |
| 20 | 30 | 55 | 61 | 67 | 73 | 86 | 90 | 102 | 108 | |
| 15 | 10 | 3 | 16 | 18 | 18 | 14 | 38 | 31 | 35 | |
| Trade Payables | 72 | 75 | 78 | 37 | 78 | 110 | 110 | 127 | 129 | 103 |
| 2 | 9 | 11 | 8 | 8 | 8 | 10 | 11 | 13 | 17 | |
| Total Liabilities | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 |
| 8 | 12 | 12 | 12 | 12 | 14 | 14 | 14 | 13 | 16 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | |
| 2 | 5 | 15 | 21 | 17 | 18 | 14 | 29 | 35 | 45 | |
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 184 | 133 | |
| Cash & Bank | 2 | 1 | 3 | 0 | 1 | 1 | 0 | 1 | 2 | 1 |
| 113 | 124 | 139 | 111 | 164 | 199 | 216 | 247 | 68 | 92 | |
| Total Assets | 125 | 142 | 170 | 146 | 194 | 233 | 245 | 291 | 303 | 291 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| 6 | 3 | -18 | 3 | 4 | 7 | 4 | 1 | -3 | 10 | |
| Cash from Investing | -3 | -5 | -1 | -1 | -1 | -3 | -3 | 0 | -2 | -6 |
| Cash from Financing | -2 | 4 | 23 | -2 | -2 | -2 | 2 | 1 | 6 | -4 |
| 1 | -1 | 2 | -3 | 0 | 0 | -0 | 1 | 1 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| PER SHARE | ||||||||||
| EPS (₹) | 0.77 | 3.03 | 2.64 | 2.80 | 2.48 | 2.79 | 2.58 | 1.49 | 1.67 | 1.41 |
| Book Value (₹) | 21.82 | 26.63 | 33.33 | 36.02 | 38.50 | 41.29 | 43.85 | 45.34 | 46.45 | 47.78 |
| Dividend per Share (₹) | 0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash EPS (₹) | 1.13 | 3.38 | 2.95 | 3.23 | 2.86 | 3.18 | 3.37 | 2.11 | 2.27 | 2.10 |
| PROFITABILITY | ||||||||||
| Operating Margin % | 1.69% | 3.27% | 3.10% | 3.45% | 3.31% | 3.35% | 2.85% | 2.49% | 1.63% | 0.61% |
| Net Margin % | 0.52% | 1.38% | 1.77% | 1.84% | 1.93% | 1.87% | 1.33% | 0.90% | 1.18% | 0.85% |
| ROE % | 3.58% | 12.90% | 9.80% | 8.07% | 6.65% | 6.98% | 6.31% | 3.33% | 3.82% | 3.02% |
| ROCE % | 7.23% | 22.21% | 14.14% | 12.05% | 8.48% | 9.46% | 9.87% | 6.28% | 6.09% | 6.38% |
| 1.07% | 4.09% | 3.96% | 4.15% | 3.41% | 3.05% | 2.74% | 1.41% | 1.58% | 1.36% | |
| EFFICIENCY | ||||||||||
| Debtor Days | 103 | 71 | 93 | 103 | 123 | 135 | 110 | 142 | 172 | 122 |
| Inventory Days | 5 | 3 | 10 | 19 | 23 | 19 | 12 | 19 | 29 | 31 |
| Payable Days | 105 | 70 | 82 | 61 | 72 | 103 | 86 | 109 | 125 | 93 |
| 3 | 5 | 21 | 60 | 74 | 51 | 36 | 52 | 76 | 60 | |
| FINANCIAL HEALTH | ||||||||||
| Debt to Equity (x) | 0.40x | 0.22x | 0.04x | 0.19x | 0.20x | 0.19x | 0.13x | 0.33x | 0.24x | 0.26x |
| Interest Coverage (x) | 2.06x | 2.84x | 5.27x | 5.03x | 5.06x | 4.40x | 5.93x | 3.10x | 2.22x | 2.31x |
| 1.32x | 1.42x | 1.78x | 2.31x | 1.81x | 1.67x | 1.73x | 1.61x | 1.70x | 1.78x | |
| GROWTH | ||||||||||
| Revenue Growth % | 15.27% | 60.94% | -11.95% | 1.74% | -15.40% | 16.10% | 41.43% | -14.98% | -5.09% | 19.19% |
| Operating Profit Growth % | 5.10% | 212.00% | -16.41% | 12.95% | -18.84% | 17.58% | 20.55% | -25.68% | 9.24% | 11.34% |
| Net Profit Growth % | 18.47% | 324.54% | 12.86% | 5.90% | -11.44% | 12.44% | 0.62% | -42.47% | 24.20% | -14.09% |
| 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 12.38% | -15.29% | |
| VALUATION | ||||||||||
| P/E (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 26.76x | 23.84x |
| P/B (x) | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.96x | 0.71x |
| Dividend Yield % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | 13.59x | 10.17x |
Documents
Corporate disclosures, annual reports, credit ratings, and concall transcripts
2026-08-20 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
2026-08-14 - Aarey Drugs & Pharmaceuticals Limited has submitted to the Exchange, the unaudited financial results for the period ended Jun 30, 2026.
2026-08-06 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on August 06, 2026.
2026-07-08 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
2026-07-06 - Nimit Rajesh Ghatalia has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
2026-07-01 - Nimit Rajesh Ghatalia has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
2026-06-26 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
2026-06-02 - Aarey Drugs & Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication of Audited Financial Results of the Company for quarter and financial year ended on March 31, 2026
2026-05-30 - Aarey Drugs & Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
News
Recent coverage and analyst commentary for AAREYDRUGS
Loading news…
AI Stock Analyst
Aarey Drugs & Pharmaceuticals Ltd.
Sign in to Chat with AI
Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.
✨ Sign In to ChatFree 5nance Account